Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo

References

• Bonci D, Coppola V, Musumeci M, et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14:1271–7
   PubMed Web of Science ®Google Scholar
• Brody EN, Gold L. (2000). Aptamers as therapeutic and diagnostic agents. J Biotechnol 74:5–13
   PubMedGoogle Scholar
• Cheng J, Teply BA, Sherifi I, et al. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28:869–76
   PubMed Web of Science ®Google Scholar
• Clevers H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127:469–80
   PubMed Web of Science ®Google Scholar
• Dassie JP, Liu XY, Thomas GS, et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–49
   PubMed Web of Science ®Google Scholar
• Dhanasekaran SM, Barrette TR, Ghosh D, et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–6
   PubMed Web of Science ®Google Scholar
• Dhar S, Gu FX, Langer R, et al. (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 105:17356–61
   PubMed Web of Science ®Google Scholar
• Dong JT, Boyd JC, Frierson HF Jr. (2001). Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 49:166–71
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak JW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–22
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Jon S, Khademhosseini A, et al. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64:7668–72
   PubMed Web of Science ®Google Scholar
• Fisher JL, Schmitt JF, Howard ML, et al. (2002). An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res 307:337–45
   PubMed Web of Science ®Google Scholar
• Honma K, Ochiya T, Nagahara S, et al. (2001). Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions. Biochem Biophys Res Commun 289:1075–81
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, et al. (2003). VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198:483–9
   PubMed Web of Science ®Google Scholar
• Keller ET, Brown J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718–29
   PubMed Web of Science ®Google Scholar
• Lu W, Takahashi H, Furusato M, et al. (2006). Allelotyping analysis at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and significant prostate cancers. Prostate 66:405–12
   PubMed Web of Science ®Google Scholar
• Lupold SE, Hicke BJ, Lin Y, Coffey DS. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029–33
   PubMed Web of Science ®Google Scholar
• Minakuchi Y, Takeshita F, Kosaka N, et al. (2004). Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32:e109
   PubMed Web of Science ®Google Scholar
• Mu P, Nagahara S, Makita N, et al. (2009). Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978–90
   PubMed Web of Science ®Google Scholar
• Ochiya T, Nagahara S, Sano A, et al. (2001). Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 1:31–52
   PubMedGoogle Scholar
• Ochiya T, Takahama Y, Nagahara S, et al. (1999). New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet Nat Med 5:707–10
   Google Scholar
• Reed JC. (1998). Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11–8
   PubMed Web of Science ®Google Scholar
• Sano A, Maeda M, Nagahara S, et al. (2003). Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev 55:1651–77
   PubMed Web of Science ®Google Scholar
• Sherr CJ. (1996). Cancer cell cycles. Science 274:1672–7
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. CA Cancer J Clin 62:10–29
   PubMed Web of Science ®Google Scholar
• Takeshita F, Minakuchi F, Nagahara S, et al. (2005). Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102:12177–82
   PubMed Web of Science ®Google Scholar
• Takeshita F, Patrawala L, Osaki M, et al. (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18:181–7
   PubMed Web of Science ®Google Scholar
• Tong R, Yala L, Fan TM, Cheng J. (2010). The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials. 31:3043–53
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–10
   PubMed Web of Science ®Google Scholar
• Visai L, Xu Y, Casolini F, et al. (2000). Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate. J Biol Chem 275:39837–45
   PubMed Web of Science ®Google Scholar
• Wu F, Wuensch SA, Azadniv M, et al. (2009). Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol Pharm 6:1506–17
   PubMed Web of Science ®Google Scholar
• Wu X, Ding B, Gao J, et al. (2011). Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6:1747–56
   PubMed Web of Science ®Google Scholar
• Xin H, Chen L, Gu J, et al. (2010). Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: in vitro and in vivo evaluation. Int J Pharm 402:238–47
   PubMed Web of Science ®Google Scholar